Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
about
Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: a whole new world with therapeutic implicationsNovel CD20 monoclonal antibodies for lymphoma therapyDiagnostic, prognostic and therapeutic role of CD30 in lymphoma.CD30 expression in malignant vascular tumors and its diagnostic and clinical implications: a study of 146 casesTyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.Brentuximab vedotin for relapsed or refractory Hodgkin lymphoma: experience in Turkey.Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma.Using antibodies to target cancer therapeutics.Targeted drug delivery for cancer therapy: the other side of antibodies.Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics.Natural product and natural product derived drugs in clinical trials.Drug Discovery by Molecular Imaging and Monitoring Therapy Response in Lymphoma.Novel anticarcinoembryonic antigen antibody-drug conjugate has antitumor activity in the existence of soluble antigenNanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer.ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates.Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey.The impact of trisulfide modification of antibodies on the properties of antibody-drug conjugates manufactured using thiol chemistry.PK of immunoconjugate anticancer agent CMD-193 in rats: ligand-binding assay approach to determine in vivo immunoconjugate stability.Site-Specific Antibody Conjugation for ADC and Beyond.Severe peripheral motor neuropathy in a patient with Hodgkin lymphoma treated with brentuximab vedotin
P2860
Q27011510-EF46DC54-9AFA-4E2C-9D4E-9D846F1127A8Q28390112-3B41E3B6-55F8-4CF7-BB13-E606A297BBAAQ30240160-DFC78D61-CA30-44EB-8B38-CE0CC7CCF730Q33595621-9DF87D4B-BEFF-4004-92EC-2CED282F3118Q34495630-8B737DC6-1B09-4988-B0F0-8C74F2DC158BQ35050554-FC017036-F309-4A50-9081-6A38CE50E65CQ35223221-74359DB7-48F4-4D4B-ABD3-6C95A95BF738Q38014920-81E91FB2-919D-46DF-87CA-6C0A9F2FD534Q38058816-CD8D7300-64E2-4050-9664-082AAAFB8045Q38087390-E088E178-57B4-4EBE-A221-D03CEAB611F8Q38092648-ECFFF11F-12AD-4EED-B781-11510E7EE94FQ38247457-9E0DC19E-10DC-49A2-9FAB-770B6B42EAA8Q41573147-1D6FCB2A-6943-4224-8111-295E9276F647Q42060421-2487FFE7-81F1-4D79-A2E6-3F1D0FBC8EBBQ47148105-F7517574-060B-401F-89DE-BD3E32925F4BQ47197303-6A532759-5F77-412C-8EEB-57EBAC8CF32EQ50873125-A9F48EFD-F31E-44CE-89E9-1165B8D7064BQ51024674-CF603A0D-A1F8-4A43-9614-C06222DA9070Q51132501-F6001B53-BC46-453C-91DB-A3AB275788DEQ55022669-B0CF9075-B4D0-4AE4-A3FD-7AA3B2275C16Q56977366-3EAD2035-2F80-49C5-9A87-91D75D6848F2
P2860
Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Brentuximab Vedotin (SGN-35), ...... of CD30-positive malignancies.
@en
Brentuximab Vedotin (SGN-35), ...... of CD30-positive malignancies.
@nl
type
label
Brentuximab Vedotin (SGN-35), ...... of CD30-positive malignancies.
@en
Brentuximab Vedotin (SGN-35), ...... of CD30-positive malignancies.
@nl
prefLabel
Brentuximab Vedotin (SGN-35), ...... of CD30-positive malignancies.
@en
Brentuximab Vedotin (SGN-35), ...... of CD30-positive malignancies.
@nl
P2860
P1476
Brentuximab Vedotin (SGN-35), ...... of CD30-positive malignancies.
@en
P2093
Antonio Gualberto
P2860
P304
P356
10.1517/13543784.2011.641532
P407
P577
2011-11-30T00:00:00Z